The risky business of dopamine agonists in Parkinson disease and impulse control disorders.
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Risk-taking behavior is characterized by pursuit of reward in spite of potential negative consequences. Dopamine neurotransmission along the mesocorticolimbic pathway is a potential modulator of risk behavior. In patients with Parkinson's disease (PD), impulse control disorder (ICD) can result from dopaminergic medication use, particularly dopamine agonists (DAA). Behaviors associated with ICD include hypersexuality as well as compulsive gambling, shopping, and eating, and these behaviors are potentially linked to alterations to risk processing. Using the Balloon Analogue Risk Task, we assessed the role of agonist therapy on risk-taking behavior in PD patients with (n = 22) and without (n = 19) active ICD symptoms. Patients performed the task both "on" and "off" DAA. DAA increased risk-taking in PD patients with active ICD symptoms, but it did not affect risk behavior of PD controls. DAA dose was also important in explaining risk behavior. Both groups similarly reduced their risk-taking in high compared to low risk conditions and following the occurrence of a negative consequence, suggesting that ICD patients do not necessarily differ in their abilities to process and adjust to some aspects of negative consequences. Our findings suggest dopaminergic augmentation of risk-taking behavior as a potential contributing mechanism for the emergence of ICD in PD patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
The debate over dopamine’s role in reward: the case for incentive salience
Berridge, K. C. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0578-x · Cited by 2,347
Evaluation of a behavioral measure of risk taking: The balloon analogue risk task (BART)
Lejuez, C. W., Read, J. P., Kahler, C. W., Richards, J. B., Ramsey, S. E., Stuart, G. L., Strong, D. R., & Brown, R. A. (2002) · Journal of Experimental Psychology: Applied · doi:10.1037/1076-898x.8.2.75 · Cited by 2,336
Discrete coding of reward probability and uncertainty by dopamine neurons
Fiorillo, C. D., Tobler, P. N., & Schultz, W. (2003) · Science · doi:10.1126/science.1077349 · Cited by 2,085
By Carrot or by Stick: Cognitive Reinforcement Learning in Parkinsonism
Frank, M. J., Seeberger, L. C., & O'Reilly, R. C. (2004) · Science · doi:10.1126/science.1102941 · Cited by 1,964
Cools, R. (2001) · Cerebral Cortex · doi:10.1093/cercor/11.12.1136 · Cited by 906 · cited 3×
“As a result, patients may appraise outcomes as relatively " better than expected " under the dopaminergic " overdosing " influence of DAA (Cools et al., 2001; Voon et al., 2010).”
Association of dopamine agonist use with impulse control disorders in Parkinson disease
Weintraub, D., Siderowf, A. D., Potenza, M. N., Goveas, J., Morales, K. H., Duda, J. E., Moberg, P. J., & Stern, M. B. (2006) · Archives of Neurology · doi:10.1001/archneur.63.7.969 · Cited by 662 · cited 1×
“DAA doses were converted to levodopa equivalent daily dose (LEDD) values (Weintraub et al., 2006).”
Lejuez, C. W., Aklin, W. M., Zvolensky, M. J., & Pedulla, C. M. (2003) · Journal of Adolescence · doi:10.1016/s0140-1971(03)00036-8 · Cited by 591
Pathological Gambling Caused by Drugs Used to Treat Parkinson Disease
Dodd, M. L., Klos, K. J., Bower, J. H., Geda, Y. E., Josephs, K. A., & Ahlskog, J. E. (2005) · Archives of Neurology · doi:10.1001/archneur.62.9.noc50009 · Cited by 563
Validation of the questionnaire for impulsive‐compulsive disorders in Parkinson's disease
Weintraub, D., Hoops, S., Shea, J. A., Lyons, K. E., Pahwa, R., Driver‐Dunckley, E. D., Adler, C. H., Potenza, M. N., Miyasaki, J., Siderowf, A. D., et al. (2009) · Movement Disorders · doi:10.1002/mds.22571 · Cited by 528
The balloon analogue risk task (BART) differentiates smokers and nonsmokers.
Lejuez, C. W., Aklin, W. M., Jones, H. A., Richards, J. B., Strong, D. R., Kahler, C. W., & Read, J. P. (2003) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.11.1.26 · Cited by 523 · cited 1×
“Two trial displays of the Balloon Analogue Risk Task. of sensation seeking and impulsivity as well as with high risk behaviors (Lejuez, Aklin, Zvolensky, et al., 2003).”
Steeves, T. D. L., Miyasaki, J., Zurowski, M., Lang, A. E., Pellecchia, G., Van Eimeren, T., Rusjan, P., Houle, S., & Strafella, A. P. (2009) · Brain · doi:10.1093/brain/awp054 · Cited by 502
Mechanisms underlying dopamine-mediated reward bias in compulsive behaviors
Voon, V., Pessiglione, M., Brezing, C., Gallea, C., Fernandez, H. H., Dolan, R. J., & Hallett, M. (2010) · Neuron · doi:10.1016/j.neuron.2009.12.027 · Cited by 280
Cited by
From prediction error to incentive salience: mesolimbic computation of reward motivation.
Berridge, K. C. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2012.07990.x · Cited by 700
Management of common adverse effects of antipsychotic medications
Stroup, T. S., & Gray, N. (2018) · World Psychiatry · doi:10.1002/wps.20567 · Cited by 572
Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update
Voon, V., Napier, T. C., Frank, M. J., Sgambato-Faure, V., Grace, A. A., Rodriguez-Oroz, M., Obeso, J., Bezard, E., & Fernagut, P.-O. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30004-2 · Cited by 359
Impulse Control and Related Disorders in Parkinson's Disease
Weintraub, D., & Claassen, D. O. (2017) · International Review of Neurobiology · doi:10.1016/bs.irn.2017.04.006 · Cited by 272
Self-citationSensation-seeking: dopaminergic modulation and risk for psychopathology
Norbury, A., & Husain, M. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.04.015 · Cited by 142
Metadata
- Authors
- Claassen, D. O., van den Wildenberg, W. P. M., Ridderinkhof, K. R., Jessup, C. K., Harrison, M. B., Wooten, G. F., & Wylie, S. A.
- Venue
- Behavioral Neuroscience
- Published
- 2011-08
- Volume
- 125
- Issue
- 4
- Pages
- 492-500
- ISSN
- 0735-7044 (ISSN-L)
- 1939-0084
- OpenAlex
- W2146710851
- Cited by
- 104
- References
- 13
- FWCI
- 6.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.